Pfizer (PFE) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
76.51% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
131.31% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
109.43% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-51.68% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
27.11% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-146.62% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
5.72% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Mar 29, 2026 |
-146.62% |
| Jun 29, 2025 |
-9.74% |
| Sep 29, 2024 |
14.94% |
| Jun 30, 2024 |
27.49% |
| Mar 31, 2024 |
-91.29% |
| Oct 1, 2023 |
-72.22% |
| Jul 2, 2023 |
-26.04% |
| Apr 2, 2023 |
-89.57% |
| Oct 2, 2022 |
-93.54% |
| Oct 3, 2021 |
-47.08% |
| Apr 4, 2021 |
44.22% |
| Jun 28, 2020 |
664.32% |
| Dec 31, 2019 |
592.52% |
| Dec 31, 2018 |
616.54% |
| Sep 30, 2018 |
11.20% |
| Apr 1, 2018 |
-30.06% |
| Dec 31, 2017 |
28.73% |
| Dec 31, 2016 |
31.63% |
| Jul 3, 2016 |
-95.44% |
| Dec 31, 2015 |
-26.10% |
| Sep 27, 2015 |
-67.12% |
| Mar 29, 2015 |
-60.15% |
| Dec 31, 2014 |
-26.16% |
| Sep 28, 2014 |
-26.64% |
| Mar 30, 2014 |
93.99% |
| Dec 31, 2013 |
15.66% |
| Sep 29, 2013 |
-24.93% |
| Jun 30, 2013 |
598.37% |
| Mar 31, 2013 |
98.68% |
| Dec 31, 2012 |
616.67% |
| Sep 30, 2012 |
382.74% |
| Apr 1, 2012 |
329.08% |
